Metallodrugs against Breast Cancer: Combining the Tamoxifen Vector with Platinum(II) and Palladium(II) Complexes

The luminal A-subtype of breast cancer, where the oestrogen receptor α (ERα) is overexpressed, is the most frequent one. The prodrug tamoxifen (1) is the clinically used agent, inhibiting the ERα activity via the formation of several active metabolites, such as 4-hydroxytamoxifen (2) or 4,4′-dihydro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazimir, Aleksandr, Schwarze, Benedikt, Lönnecke, Peter, Jelača, Sanja, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Hey-Hawkins, Evamarie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959148/
https://www.ncbi.nlm.nih.gov/pubmed/36840003
http://dx.doi.org/10.3390/pharmaceutics15020682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959148/
https://www.ncbi.nlm.nih.gov/pubmed/36840003
http://dx.doi.org/10.3390/pharmaceutics15020682

Ejemplares similares